Business Wire

ADVA

Share
ADVA manages supply constraints and grows revenues and profitability in Q3 2021

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported its financial results for Q3 2021 ended on September 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005879/en/

Q3 2021 financial summary1

(in thousands of EUR)

 

Q3

 

Q3

 

Change

 

Q2

 

Change

 

 

2021

 

2020

 

 

 

2021

 

 

 

Revenues

 

151,777

 

146,676

 

3.5%

 

149,354

 

1.6%

Pro forma gross profit

 

52,153

 

51,930

 

0.4%

 

57,274

 

-8.9%

in % of revenues

 

34.4%

 

35.4%

 

-1.0pp

 

38.3%

 

-3.9pp

Pro forma operating income

 

13,012

 

11,053

 

17.7%

 

14,415

 

-9.7%

in % of revenues

 

8.6%

 

7.5%

 

1.1pp

 

9.7%

 

-1.1pp

Operating income (loss)2

 

9,496

 

9,768

 

-2.8%

 

13,036

 

-27.2%

Net income

 

18,478

 

6,671

 

177.0%

 

12,001

 

54.0%

 

(in thousands of EUR)

 

Sep. 30

2021

 

Sep. 30

2020

 

Change

 

Jun. 30

2021

 

Change

Cash and cash equivalents

 

100,513

 

68,293

 

47.2%

 

85,023

 

18.2%

Net cash (+) / Net debt (-)

 

20,610

 

-35,009

 

n.a.

 

3,876

 

431.7%

Net working capital

 

130,794

 

124,043

 

5.4%

 

132,767

 

-1.5%

1 Potential difference due to rounding
2 Q3 2021 including EUR 2.1 million extraordinary expenses

Q3 2021 IFRS financial results
Revenues in Q3 2021 reached EUR 151.8 million, up by 1.6% from EUR 149.4 million in Q2 2021, also up by 3.5% compared to EUR 146.7 million in Q3 2020. The increase in revenues is predominantly driven by a growth in demand from communication service providers (CSPs).

Pro forma gross profit in Q3 2021 decreased by 8.9%, reaching EUR 52.2 million (34.4% of revenues) compared to EUR 57.3 million (38.3% of revenues) in Q2 2021 and increased by 0.4% compared to EUR 51.9 million (35.4% of revenues) reported in Q3 2020. The reduction in gross profit compared to the previous quarter is mainly attributable to the semiconductor crisis, which led to increased purchasing costs.

Pro forma operating income for Q3 2021 was EUR 13.0 million (8.6% of revenues) and decreased by 9.7% compared to EUR 14.4 million (9.7% of revenues) reported in Q2 2021. Compared to Q3 2020, pro forma operating income improved substantially by 17.7% from EUR 11.1 million (7.5% of revenues).

Operating income for Q3 2021 of EUR 9.5 million decreased substantially by 27.2% from EUR 13.0 million reported for Q2 2021 and slightly decreased by 2.8% from EUR 9.8 million in Q3 2020. Operating income for Q3 2021 was impacted by extraordinary expenses in connection with the announced merger with ADTRAN amounting to EUR 2.1 million.

Net income reached EUR 18.5 million in Q3 2021, substantially up by 54.0% from EUR 12.0 million in Q2 2021, and significantly up by 177.0% from EUR 6.7 million in Q3 2020. The significant increase in net income is mainly due to a tax benefit of EUR 8.8 million resulting from increased deferred tax assets.

The company’s cash and cash equivalents totaled EUR 100.5 million, representing an increase of EUR 15.5 million compared to EUR 85.0 million at the end of Q2 2021. Year-over-year cash and cash equivalents substantially increased by EUR 32.2 million from EUR 68.3 million at the end of Q3 2020.

Net cash at the end of Q3 2021 stood at EUR 20.6 million compared to a net cash position of EUR 3.9 million at the end of Q2 2021 or a net debt position of EUR 35.0 million at the end of Q3 2020.

Net working capital at quarter-end was EUR 130.8 million and decreased by EUR 2.0 million compared to EUR 132.8 million at the end of Q2 2021 and increased by EUR 6.8 million compared to EUR 124.0 million at the end of Q3 2020.

Management commentary
“Customer demand for our solutions remains strong and we’re fighting hard to overcome the current supply chain challenges,” said Brian Protiva, CEO, ADVA. “We’re also looking forward to the planned business combination with ADTRAN. Our industry is in the early stages of an unprecedented investment cycle in fiber expansion propelled by the goal of delivering high-speed connectivity to all homes, businesses and the future 5G infrastructure. This expansion of the digital infrastructure requires new, innovative solutions and drives convergence at the network edge. Together with ADTRAN, we’re creating a market and innovation leader in this space that offers the industry’s most comprehensive and unique portfolio of solutions based on openness, scalability, security and software-controlled automation.”

“In view of the global semiconductor crisis, the third quarter was definitely challenging. Nevertheless, we managed to grow and generate solid margins. In addition, we were able to generate cash, and with more than EUR 100 million cash and a net cash position of around EUR 21 million, we further improved our level of financial flexibility,” said Uli Dopfer, CFO, ADVA. “The semiconductor crisis will last longer than we originally assumed, and the coming weeks and months will certainly be demanding again. Nevertheless, we are confident that with these strong numbers and order books at a record level, we will be able to overcome these supply challenges and close the year with good results within our outlook.”

Financial outlook 2021
For the fiscal year 2021, ADVA still expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 7.0% and 10.0% of revenues.

The company will publish its financial results for Q4 and the full fiscal year 2021 on February 24, 2022.

Conference call details
ADVA will hold a conference call for analysts and investors today, October 21, 2021, to discuss the Q3 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete quarterly statement 9M 2021 (January – September) is available as a PDF:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye